The production of monoclonal antibodies (mAbs) was pioneered by Georges Kohler and Cesar Milstein in 1975 - a discovery recognised by the award, in 1984, of the Nobel Prize for Physiology or Medicine.
Together with Dr. Claudio Cuello, one of MédiMabs co-founders, Dr. Milstein established the foundation for the use of monoclonal antibodies for the investigation of pathological pathways in neurological disorders as well as many other diseases. Their collaboration resulted in the report of the first monoclonal antibody for Neuroscience application (anti-substance P) by Dr. Cuello's laboratory in Oxford. As MédiMabs’ founder and CSO, Dr. Cuello imported his knowledge to the scientific team who have become experts in the procedure.
MédiMabs is recognized and solicited for the personalized services they offer for the development of monoclonal antibodies. MédiMabs’ aim is to generate antibodies that recognize not only the immunizing agent but the entire target protein so as to ensure it functions in client’s application in the most satisfactory manner.
MédiMabs’ highly skilled technical staff works together with each client throughout all steps of the project, from the designing of the antigen, the immunization strategy to the clones screening and testing of final product. Their objective is always to maximize the success of the client’s antibody project and reach total client’s satisfaction.
MédiMabs’ standard protocol for monoclonal antibodies production requires approximately 4 to 6 months to be completed. The process is divided in 4 phases with phase 2 being the Go/No Go phase at which point the project can be aborted should the pre-fusion screening does not meet client’s expectations:
Although each phase is highly important for the production of monoclonal antibodies, the determination of best the antigen (peptide, recombinant protein or whole cell immunization) and the immunization strategy are critical. MédiMabs designs the most pertinent peptides thanks to a deep analysing of the client’s protein of interest. A report of the results of the analysis is provided to the client to facilitate the selection of the best candidate(s). It is only when the antigen is perfectly designed that the project is launched.
After the immunization phase and the preliminary ELISA testing of the polyclonal sera, the client is asked to test these in their desired application to identify the best animal(s) they wish to proceed with to phase 2, fusion and clone selection. Phase 2 consists of fusing splenocytes from the chosen animal to mouse or rat myeloma cells. The resulting hybridoma cells are screened and antigen-positive hybridoma cells are selected. The screening process involves the collection of individual clones by a fully automated high-throughput colony picking Robot. This instrument identifies hybridoma clones growing on solid media, picks them and duplicates them onto liquid media. This process delivers performance and unparalleled precision; the sensitivity and precision of its software and camera allows for a larger number of clones to be selected and eliminate random choices of clones made by human eyes. Once clones have been picked their supernatants are tested in ELISA.
ELISA positive clones are isolated and a sample of their supernatant containing the antibodies are sent out to the client so they can be evaluated for their application. MédiMabs provides up to 10 positive clones per project.
Phase 3 consists in expanding the client’ selected clones and freezing samples of the hybridomas.
Phase 4 involves the final delivery of the vials of antibody and the frozen respective hybridomas. At MédiMabs, the IP of the newly generated antibody remains with the client.
MédiMabs offers the client the option to commercialize the antibody to the research community via a license offering royalties.
MédiMabs offers to the client a wide range of post generation services such as: hybridoma expansion and banking, large scale cell culture supernatant production or by mouse ascites fluid, monoclonal antibody purification and isotyping.
Please, contact us to obtain more information or to request a quote.